Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 173.06 USD -2.53% Market Closed
Market Cap: 10.4B USD

Wall Street
Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 226.12 USD with a low forecast of 195.94 USD and a high forecast of 303.45 USD.

Lowest
Price Target
195.94 USD
13% Upside
Average
Price Target
226.12 USD
31% Upside
Highest
Price Target
303.45 USD
75% Upside
Ascendis Pharma A/S Competitors:
Price Targets
2696
Shanghai Henlius Biotech Inc
22% Downside
2162
KeyMed Biosciences Inc
28% Upside
2487
Cutia Therapeutics
6% Upside
XGN
Exagen Inc
9% Upside
MDGL
Madrigal Pharmaceuticals Inc
55% Upside
VCYT
Veracyte Inc
54% Upside
REGN
Regeneron Pharmaceuticals Inc
60% Upside
SPRY
ARS Pharmaceuticals Inc
122% Upside

Revenue
Forecast

Revenue Estimate
Ascendis Pharma A/S

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 3 years is 69%.

30%
Past Growth
69%
Estimated Growth
Estimates Accuracy
4%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Ascendis Pharma A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-19%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ASND's stock price target?
Price Target
226.12 USD

According to Wall Street analysts, the average 1-year price target for ASND is 226.12 USD with a low forecast of 195.94 USD and a high forecast of 303.45 USD.

What is Ascendis Pharma A/S's Revenue forecast?
Projected CAGR
69%

For the last 11 years the compound annual growth rate for Ascendis Pharma A/S's revenue is 30%. The projected CAGR for the next 3 years is 69%.

Back to Top